Some mutations in the FGFR4 kinase domain (N535K and V550E) lead to sustained activation of the FGFR4 signaling pathway in rhabdomyosarcoma [6], malignant lung adenoma and glioma [4, 11, 12]. This evidence concerns the gene FGFR4 and rhabdomyosarcoma.